Cargando…

Management of splanchnic vein thrombosis

The expression splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis. These disorders have common characteristics: they are both rare diseases which can cause portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkrief, Laure, Payancé, Audrey, Plessier, Aurélie, d’Alteroche, Louis, Ronot, Maxime, Paradis, Valérie, Valla, Dominique, Rautou, Pierre-Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023986/
https://www.ncbi.nlm.nih.gov/pubmed/36941824
http://dx.doi.org/10.1016/j.jhepr.2022.100667
_version_ 1784909008274980864
author Elkrief, Laure
Payancé, Audrey
Plessier, Aurélie
d’Alteroche, Louis
Ronot, Maxime
Paradis, Valérie
Valla, Dominique
Rautou, Pierre-Emmanuel
author_facet Elkrief, Laure
Payancé, Audrey
Plessier, Aurélie
d’Alteroche, Louis
Ronot, Maxime
Paradis, Valérie
Valla, Dominique
Rautou, Pierre-Emmanuel
author_sort Elkrief, Laure
collection PubMed
description The expression splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis. These disorders have common characteristics: they are both rare diseases which can cause portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of underlying liver disease share many risk factors, among which myeloproliferative neoplasms represent the most common; a rapid comprehensive work-up for risk factors of thrombosis is needed in these patients. Long-term anticoagulation is indicated in most patients. Portal vein thrombosis can also develop in patients with cirrhosis and in those with porto-sinusoidal vascular liver disease. The presence and nature of underlying liver disease impacts the management of portal vein thrombosis. Indications for anticoagulation in patients with cirrhosis are growing, while transjugular intrahepatic portosystemic shunt is now a second-line option. Due to the rarity of these diseases, studies yielding high-grade evidence are scarce. However, collaborative studies have provided new insight into the management of these patients. This article focuses on the causes, diagnosis, and management of patients with Budd-Chiari syndrome, portal vein thrombosis without underlying liver disease, or cirrhosis with non-malignant portal vein thrombosis.
format Online
Article
Text
id pubmed-10023986
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100239862023-03-19 Management of splanchnic vein thrombosis Elkrief, Laure Payancé, Audrey Plessier, Aurélie d’Alteroche, Louis Ronot, Maxime Paradis, Valérie Valla, Dominique Rautou, Pierre-Emmanuel JHEP Rep Review The expression splanchnic vein thrombosis encompasses Budd-Chiari syndrome and portal vein thrombosis. These disorders have common characteristics: they are both rare diseases which can cause portal hypertension and its complications. Budd-Chiari syndrome and portal vein thrombosis in the absence of underlying liver disease share many risk factors, among which myeloproliferative neoplasms represent the most common; a rapid comprehensive work-up for risk factors of thrombosis is needed in these patients. Long-term anticoagulation is indicated in most patients. Portal vein thrombosis can also develop in patients with cirrhosis and in those with porto-sinusoidal vascular liver disease. The presence and nature of underlying liver disease impacts the management of portal vein thrombosis. Indications for anticoagulation in patients with cirrhosis are growing, while transjugular intrahepatic portosystemic shunt is now a second-line option. Due to the rarity of these diseases, studies yielding high-grade evidence are scarce. However, collaborative studies have provided new insight into the management of these patients. This article focuses on the causes, diagnosis, and management of patients with Budd-Chiari syndrome, portal vein thrombosis without underlying liver disease, or cirrhosis with non-malignant portal vein thrombosis. Elsevier 2023-01-03 /pmc/articles/PMC10023986/ /pubmed/36941824 http://dx.doi.org/10.1016/j.jhepr.2022.100667 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Elkrief, Laure
Payancé, Audrey
Plessier, Aurélie
d’Alteroche, Louis
Ronot, Maxime
Paradis, Valérie
Valla, Dominique
Rautou, Pierre-Emmanuel
Management of splanchnic vein thrombosis
title Management of splanchnic vein thrombosis
title_full Management of splanchnic vein thrombosis
title_fullStr Management of splanchnic vein thrombosis
title_full_unstemmed Management of splanchnic vein thrombosis
title_short Management of splanchnic vein thrombosis
title_sort management of splanchnic vein thrombosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023986/
https://www.ncbi.nlm.nih.gov/pubmed/36941824
http://dx.doi.org/10.1016/j.jhepr.2022.100667
work_keys_str_mv AT elkrieflaure managementofsplanchnicveinthrombosis
AT payanceaudrey managementofsplanchnicveinthrombosis
AT plessieraurelie managementofsplanchnicveinthrombosis
AT dalterochelouis managementofsplanchnicveinthrombosis
AT ronotmaxime managementofsplanchnicveinthrombosis
AT paradisvalerie managementofsplanchnicveinthrombosis
AT valladominique managementofsplanchnicveinthrombosis
AT rautoupierreemmanuel managementofsplanchnicveinthrombosis